Core Viewpoint - The strategic cooperation between Nuotai Bio and Nuowei Zhan aims to establish a joint biopharmaceutical company focused on synthetic biology technology, enhancing both companies' capabilities in the field [1][2][3] Group 1: Partnership Details - Nuotai Bio will hold a 51% stake in the joint venture, while Nuowei Zhan will hold 49%, with respective contributions of 45.90% and 44.10% [1] - The partnership will be implemented in two phases, with the first phase focusing on the renovation of existing capacities and the application for DMF of raw materials [1] - The ultimate goal is to establish an annual production capacity of approximately 10 tons of raw materials and corresponding formulations [1] Group 2: Company Strengths - Nuotai Bio is a leading company in the peptide drug sector, having overcome production bottlenecks and achieved industry-leading production levels of over 10 kilograms per batch for drugs like Semaglutide and Aibowei [2] - Nuowei Zhan specializes in the development of functional proteins and high molecular organic materials, holding a leading position in the field of in vitro diagnostic reagents [2] Group 3: Strategic Implications - The collaboration is expected to leverage the strengths of both companies in synthetic biology and peptide drugs, driving product and technology upgrades [3] - The strategic partnership aims to establish an advanced synthetic biology technology platform, promoting interdisciplinary collaboration and industry upgrades [3]

Core Points - Notai Bio (688076) closed at 50.17 yuan on June 6, 2025, up 4.39% from last week's 48.06 yuan [1] - The company's market capitalization is currently 11.282 billion yuan, ranking 41st out of 150 in the chemical pharmaceutical sector and 1402nd out of 5148 in the A-share market [1] Company Announcements - Notai Bio announced a cash dividend of 0.80 yuan per share and a stock bonus of 0.40 shares per share, with the record date set for June 11, 2025 [2] - The total cash dividend distribution amounts to 179.896 million yuan based on the pre-distribution total share capital of 224,870,915 shares, resulting in a new total share capital of 314,819,281 shares after the distribution [2] - The profit distribution and stock bonus plan was approved at the annual shareholders' meeting on May 23, 2025 [2] Tax Implications - Different tax policies apply to various types of shareholders regarding cash dividends, with natural person shareholders holding unrestricted shares for over one year exempt from personal income tax on dividend income [2] - For qualified foreign institutional investors (QFII) and Hong Kong market investors, a 10% withholding tax applies, resulting in a net cash dividend of 0.72 yuan per share [2] - Other institutional investors and corporate shareholders will receive a pre-tax cash dividend of 0.80 yuan per share [2] Earnings Impact - After the implementation of the stock bonus plan, the diluted earnings per share for the fiscal year 2024 is projected to be 1.34 yuan based on the new total share capital [2]

Core Viewpoint - Nanjing Novogene Bioinformatics Technology Co., Ltd. has signed a strategic cooperation agreement with Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. to establish a joint venture focused on synthetic biology, aiming to enhance technological advancements and project collaboration in the field [1][2]. Agreement Signing Overview - The strategic cooperation agreement does not require approval from the company's board of directors or shareholders [2]. - The agreement does not constitute a related party transaction or a major asset restructuring [2]. - The specific investment scale and construction plan for the joint venture will be determined later, indicating uncertainty [1][2]. Parties Involved - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. is a publicly listed company with a registered capital of 224.87 million yuan and was established in March 2009 [2][3]. - The company has total assets of approximately 507.80 million yuan and a net profit attributable to shareholders of 40.44 million yuan [3]. Joint Venture Details - The joint venture will be co-owned, with Nanjing Novogene holding 49% and Jiangsu Nuotai holding 51% [1][4]. - The project will be implemented in two phases, with the first phase focusing on the renovation and expansion of existing production capacities [4]. - The ultimate goal is to establish an annual production capacity of approximately 10 tons of raw materials and corresponding formulations [4]. Investment and Funding - The specific investment amount will be confirmed by both parties [4]. - Initial funding will come from self-owned funds, with potential project financing for the second phase [4]. Governance Structure - The joint venture will have a board of directors composed of three directors from Jiangsu Nuotai and two from Nanjing Novogene [5]. - The management team will include a general manager nominated by Jiangsu Nuotai and other key positions filled through mutual agreement [5][6]. Operational Management - The joint venture will operate independently, with both parties sharing operational risks and responsibilities [6]. - The agreement includes non-competition clauses and stipulates that both parties will support each other in their respective areas of expertise [6][7]. Impact on Company - This strategic cooperation is expected to enhance the company's core competitiveness in the synthetic biology sector and extend its industrial value chain [7]. - The establishment of the joint venture is subject to regulatory approval and is not expected to significantly impact the company's 2025 performance [7][8].

证券代码：688076 证券简称：诺泰生物 公告编号：2025-049 江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露签订战略合作协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"或"诺泰生 物"）与南京诺唯赞生物科技股份有限公司（以下简称"诺唯赞"）近日于南京市 签署《合成生物学合作项目战略合作协议》（以下简称"战略合作协议"或"协 议"），以合成生物学技术平台为基础，结合有机合成、化学工艺等交叉技术，共 同推进双方在合成生物学领域的技术进步和项目合作。 公司拟与诺唯赞共同设立一家生物制药公司（以下简称"合资公司"或 "项目公司"，具体名称待定，以市场监督管理机关登记的最终名称为准），公司 持股比例为 51%，诺唯赞持股比例为 49%，合资公司设立后将被纳入公司合并报 表范围内，以此为平台开展后续合作及具体业务。合作项目的具体投资规模、建 设方案等事项将由双方另行约定并履行内部审议程序，尚具有不确定性。本投资 事项不构成关联交易，也不构成重大资产 ...

诺唯赞公告，公司与诺泰生物签署《合成生物学合作项目战略合作协议》，并计划共同设立一家生物制 药公司，公司持股比例为49%，诺泰生物持股比例为51%。该合资公司将作为平台，推进双方在合成生 物学领域的技术进步和项目合作。合作项目的具体投资规模、建设方案等事项将由双方另行约定并履行 内部审议程序。合资公司未来业务开展受多方面因素影响，存在不确定性。 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股现金红利0.80元 每股转增0.40股 本次利润分配及转增股本方案经公司2025年5月23日的2024年年度股东大会审议通过。 二、分配、转增股本方案 1.发放年度：2024年年度 本次利润分配及转增股本以方案实施前的公司总股本224,870,915股为基数，每股派发现金红利0.80元 （含税），以资本公积金向全体股东每股转增0.40股，共计派发现金红利179,896,732.00元，转增 89,948,366股，本次分配后总股本为314,819,281股。 三、相关日期 ■ 四、分配、转增股本实施办法 1.实施办法 （1）本次权益分派的现金红利委托中国结算上海分公司通过其资金清算系统向股权登记日上海证券交 易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办理指定交易的投资者 可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易的股东红利暂由中国结算上海分 公司保管，待办理指定交易后再进行派发。 （2）公司本次以资本公积转增股 ...

Key Points - The company has completed the listing and circulation of all shares from its initial strategic placement [1] - There is no involvement in differentiated dividend distribution or capital increase [1] - The profit distribution and capital increase plan was approved at the annual general meeting on May 23, 2025 [2] - The total share capital before the distribution was 224,870,915 shares, with a cash dividend of 0.80 RMB per share and a capital increase of 0.40 shares per share [2][3] - The total cash dividend distributed amounts to 179,896,732 RMB, and the total shares after the distribution will be 314,819,281 [2][6] - The cash dividend will be distributed through the China Securities Depository and Clearing Corporation Limited Shanghai Branch [2] - For individual shareholders, the tax treatment on dividends varies based on the holding period, with different tax rates applied [4][5] - The company will not withhold corporate income tax for institutional investors, who will be responsible for their own tax payments [6]

证券代码：688076 证券简称：诺泰生物 公告编号：2025-048 江苏诺泰澳赛诺生物制药股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 新增无限售条件流 | 现金红利发放日 | | --- | --- | --- | --- | | | | 通股份上市日 | | | 2025/6/11 | 2025/6/12 | 2025/6/12 | 2025/6/12 | 一、通过分配、转增股本方案的股东大会届次和日期 本次利润分配及转增股本方案经公司2025 年 5 月 23 日的2024年年度股东大 会审议通过。 二、分配、转增股本方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 公司存在首发战略配售股份，首发战略配售股份已全部上市流通 是否涉及差异化分红送转：否 每股分配比例，每股转增比例 每股现金红利0.80元 每股转增0.4 ...

剂型：片剂 规格：50mg 申请事项：药品注册（境内生产） 证券代码：688076 证券简称：诺泰生物 公告编号：2025-047 江苏诺泰澳赛诺生物制药股份有限公司 关于自愿披露马来酸氟伏沙明片获得药品注册证书 的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏诺泰澳赛诺生物制药股份有限公司（以下简称"公司"）于近日收到国 家药品监督管理局核准签发的马来酸氟伏沙明片的《药品注册证书》（证书编号： 2025S01365），现将相关情况公告如下： 一、《药品注册证书》的主要内容 药品名称：马来酸氟伏沙明片 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 二、药品相关情况 马来酸氟伏沙明片是一种 SSRIs 类抗抑郁药，用于治疗抑郁症和强迫症。马 来酸氟伏沙明片由雅培制药（Abbott Laboratories (Singapore) Pri ...

证券代码：688076 证券简称：诺泰生物 公告编号：2025-046 资本公积转增股本总额:公司 2024 年度拟以资本公积向全体股东每 10 股转增 4 股不变，转增股本的数量由 87,912,038 股调整为 89,948,366 股（具体 以中国证券登记结算有限责任公司上海分公司最终登记结果为准，如有尾差，系 取整所致）。 本次调整原因:自 2025 年 3 月 31 日至本公告披露日，公司公开发行的可 转换公司债券"诺泰转债"处于转股期，转股数量为 5,090,821 股。上述事项导 致公司总股本由 219,780,094 股增加至 224,870,915 股。公司按照维持每股分配 比例不变、每股转增比例不变的原则，对公司 2024 年度利润分配及资本公积转 增股本方案中的现金分红总额、转增股本总额进行相应调整（具体以中国证券登 记结算有限责任公司上海分公司最终登记结果为准，如有尾差，系取整所致）。 一、调整前利润分配、资本公积转增股本方案 江苏诺泰澳赛诺生物制药股份有限公司 关于调整 2024 年度利润分配现金分红总额 及资本公积转增股本总额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚 ...